Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.44 |
| ▸ | TUBB | P07437 | 3/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.44 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.44 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.44 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.44 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.44 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31241506 | 1.00 | TAAR1 (0.46) | TAAR1SMN1; SMN2ADRA2AADRA2BADRA2C | |
| SCHEMBL29420719 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2ADRA2AADRA2BADRA2CTUBB4A | |
| SCHEMBL218213 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2ADRA2AADRA2BADRA2CTUBB4A | |
| SCHEMBL27762054 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2ADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL381604 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2ADRA2AADRA2BADRA2CTUBB4A | |
| SCHEMBL11082623 | 0.78 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1RAB9ANPC1L3MBTL1 | |
| SCHEMBL1842317 | 0.77 | SMN1; SMN2 (0.48) | TAAR1SMN1; SMN2ADRA2AADRA2BADRA2C | |
| SCHEMBL8151194 | 0.76 | ADRA2A (0.43) | SMN1; SMN2ADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL20222282 | 0.76 | TAAR1 (0.47) | TAAR1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL27820210 | 0.75 | SMN1; SMN2 (0.43) | TAAR1SMN1; SMN2ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024159724-A1 | O-BIPHENYL OXAZOLINE COMPOUND AND SYNTHESIS METHOD THEREFOR | 科莱博(江苏)科技股份有限公司 | 2024-08-08 | — | — | WO | disclosed |
| CN-101255209-A | Diene polymer and process for producing the same | SUMITOMO CHEMICAL CO (JP) | 2008-09-03 | — | — | CN | disclosed |
| EP-1237878-B1 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | HOFFMANN LA ROCHE (CH) | 2007-03-21 | — | — | EP | disclosed |
| CN-1771236-A | Optically active bisoxazoline compound, process for producing the same, and use thereof | SUMITOMO CHEMICAL CO (JP) | 2006-05-10 | — | — | CN | disclosed |
| CN-1231456-C | Process for preparing optically active cyclopropyl carboxylic acid derivative | SUMITOMO CHEMICAL CO (JP) | 2005-12-14 | — | — | CN | disclosed |
| US-6916933-B2 | 4-pyridinyl-n-acyl-l-phenylalanines | HOFFMAN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1244625-B1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| EP-1154993-B1 | THIOAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-06 | — | — | EP | disclosed |
| US-20040127706-A1 | 4-Pyridinyl-n-acyl-l-phenylalanines | KAPLAN GERALD LEWIS (US) | 2004-07-01 | — | — | US | disclosed |
| EP-1005445-B1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-05-26 | — | — | EP | disclosed |
| EP-0612317-A1 | SUBSTITUTED HETEROCYCLES AS ANGIOTENSIN II ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-08-31 | — | — | EP | disclosed |
| WO-1994002467-A1 | IMIDAZOLE ETHERS HAVING A II ANTAGONIST ACTIVITY | INSTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 1994-02-03 | — | — | WO | disclosed |
| US-5256781-A | Anticholesterol, antilipemic, hypotensive agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-10-26 | — | — | US | disclosed |
| US-5236934-A | Angiotensin inhibitors | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-08-17 | — | — | US | disclosed |
| US-5236925-A | Hypotensive agents, treatment of congestive heart failure | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-08-17 | — | — | US | disclosed |
| WO-1993008170-A1 | SUBSTITUTED HETEROCYCLES AS ANGIOTENSIN II ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-04-29 | — | — | WO | disclosed |
| US-5187168-A | Hypotensive agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-02-16 | — | — | US | disclosed |
| EP-0124476-B1 | CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1988-06-22 | — | — | EP | disclosed |
| US-4559349-A | TREATMENT OF PHYCHOSIS | CIBA GEIGY CORPORATION (US) | 1985-12-17 | — | — | US | disclosed |
| EP-0124476-A1 | Carboxamides, process for their preparation and pharmaceutical preparations containing them | CIBA-GEIGY AG (CH) | 1984-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127706-A1 | 4-Pyridinyl-n-acyl-l-phenylalanines | VCAM1, ICAM1, SELPLG | TAAR1 1874/4885SMN1; SMN2 2206/4885ADRA2A 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.